TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00876941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Brief Intervention
Description: Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Intervention
Description: Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Information and Feedback
Description: Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
Study: NCT02314117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV
Study: NCT02894749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D rotational angiography (3DRA)
Description: 3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
Study: NCT01336439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A (Meditoxin®)
Description: In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A (Meditoxin®)
Description: In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography.
Study: NCT02878330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: A single IM dose of 50 mg on Day 1 of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
Study: NCT04402957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution
Study: NCT03782350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Dosage 1
Description: Tranexamic Acid Dosage 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Dosage 2
Description: Tranexamic Acid Dosage 2
Study: NCT01142180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAE
Description: The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TAE
Description: No TAE procedure will be performed after endoscopic treatment
Study: NCT02369536

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutraceutical mixture
Description: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
Study: NCT01600287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAADS
Description: In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual propofol administration
Description: In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value.
Study: NCT02040714

Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.

Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.

Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.

Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
Study: NCT03429998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab
Description: evolocumab 140 mg/biweekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab and LDL apheresis
Description: evolocumab 140 mg/biweekly LDL-apheresis monthly

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LDL apheresis
Description: LDL apheresis biweekly
Study: NCT00980330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
Study: NCT02040714

Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.

Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.

Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.

Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
Study: NCT03580798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed graft
Description: 8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous graft
Description: At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
Study: NCT01285830

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
Study: NCT02040714

Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.

Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.

Intervention type: PROCEDURE
Intervention: Nonoperative Observation
Description: Group will not undergo any surgical or invasive procedures during course of treatment.

Intervention type: PROCEDURE
Intervention: Nonoperative Observation
Description: Group will not undergo any surgical or invasive procedures during course of treatment.
Study: NCT01679951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (3 mg)
Description: Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (10 mg)
Description: Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (30 mg)
Description: Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
Study: NCT00316836

Intervention type: PROCEDURE
Intervention: mammography
Study: NCT04021615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training
Description: A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training
Description: The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
Study: NCT01039688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 5 mg BID for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 10 mg BID for 24 months
Study: NCT00734344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitibine
Description: 200mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitibine
Description: 200mg once daily
Study: NCT02040714

Intervention type: PROCEDURE
Intervention: Nonoperative Observation
Description: Group will not undergo any surgical or invasive procedures during course of treatment.

Intervention type: PROCEDURE
Intervention: Nonoperative Observation
Description: Group will not undergo any surgical or invasive procedures during course of treatment.
Study: NCT01771952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc-One™
Description: A single 6cc injection of Synvisc-One™ will be utilized in this study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: A single needle stick without arthrocentesis or injection.
Study: NCT01289080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: administered orally
Study: NCT03352375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Interventions used for airway safety and ventilation during surgical procedures
Study: NCT01039688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disease-modifying antirheumatic drug
Description: Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
Study: NCT04507035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules
Description: Using anlotinib of 2 cycles as the first-line therapy.
Study: NCT00156715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
Study: NCT01070498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
Study: NCT01801878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose SVF cell
Description: adipose SVF cell transfer to the half of irradiated breast
Study: NCT03301025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg capsule, one h preinduction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given a placebo identical capsule once one hour before anesthesia
Study: NCT04102462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Capsules
Study: NCT00734344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil once daily
Description: 300mg once daily